Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679209 | 0.82 | GAA (0.58) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL1868142 | 0.76 | ALDH1A1 (0.55) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL1863520 | 0.74 | GAA (1.00) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL1864184 | 0.74 | GAA (0.61) | GAAKDM4ERAB9ANPC1KMT2A | |
| SCHEMBL13809683 | 0.73 | GAA (0.51) | GAAKDM4ERAB9ANPC1MAPK1 | |
| SCHEMBL13679210 | 0.72 | RAB9A (0.55) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL27996731 | 0.72 | SMN1; SMN2 (0.73) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL1347376 | 0.72 | GAA (0.65) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL1859594 | 0.70 | SMN1; SMN2 (0.52) | GAASMN1; SMN2KDM4ERAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL9825967 | 0.70 | KDM4E (0.48) | GAAKDM4ERAB9ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| EP-1478364-B1 | SELECTIVE ANTIBACTERIAL AGENTS | QUONOVA LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20040063765-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3227/4885SMN1; SMN2 2316/4885KDM4E 3680/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885SMN1; SMN2 2336/4885KDM4E 3715/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885SMN1; SMN2 2336/4885KDM4E 3715/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3234/4885SMN1; SMN2 2336/4885KDM4E 3715/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | GAA 3223/4885SMN1; SMN2 2331/4885KDM4E 3712/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | GAA 3240/4885SMN1; SMN2 2207/4885KDM4E 3704/4885 |
| US-20040063765-A1 | Modulation of pathogenicity | NR1H4, NR4A1, MSR1 | GAA 3255/4885SMN1; SMN2 2492/4885KDM4E 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.